Neurolymphomatosis is a rare neurological syndrome in lymphomas. It is reported as infiltration of peripheral nerves by lymphoma. It is important to distinguish neurolymphomatosis from other types of neuropathies, particularly infectious and inflammatory conditions. However, it is difficult to isolate a cancer-related inflammatory vasculitis and mononeuritis multiplex without definitive histopathologic examination. In this report, we describe a case of non-Hodgkin's lymphoma involving the peroneal nerve and presenting as neurolymphomatosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinimag.2016.08.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lymphoma Masquerading as Radiculoneuropathy: A Rare Presentation of Neurolymphomatosis.
Ann Indian Acad Neurol
November 2024
Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
The natural history of neurolymphomatosis.
BJC Rep
April 2024
Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA.
Background: Neurolymphomatosis is a lymphoid malignancy of the peripheral nervous system and its natural history is poorly understood.
Methods: We performed PubMed search and extracted clinical data for Kaplan-Meier statistics to determine outcome parameters over time. Kruskal-Wallis test was performed to compare prognostic factors.
Chromosomal Abnormalities as a Predisposition to Secondary Neurolymphomatosis in Patients with Diffuse Large B-Cell Lymphoma: A Report of Two Cases and a Literature Review.
Case Rep Oncol
October 2024
Division of Hematology, Department of Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Article Synopsis
- Neurolymphomatosis (NL) is a rare condition where lymphoma cells invade the peripheral nervous system, and its treatment options and prognosis are not well-defined.
- This study investigates predictive factors for secondary NL, revealing common chromosomal abnormalities, like deletions on chromosome 10, which may aid in early detection.
- When patients with diffuse large B-cell lymphoma show neurological symptoms and chromosomal abnormalities, there’s a potential risk for developing secondary NL that should be evaluated.
Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis.
Am J Hematol
December 2024
Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
Lymphomatous infiltration of the peripheral nervous system (PNS), termed neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has emerged as a safe and effective treatment for B-cell lymphomas. We aimed to assess toxicity and efficacy of CD19-CAR T-cells in neurolymphomatosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!